Apexigen to Present at Investor Conferences in March and April 2021
San Carlos, CA – March 1, 2021 – Apexigen, Inc., a clinical-stage biopharmaceutical company, today announced that Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer, will present at the following upcoming investor conferences:
Barclays Global Healthcare Conference being held March 9 to 11, 2021
The Company’s presentation will be available to conference registrants on Tuesday, March 9 at 2:25pm Eastern Time.
H.C. Wainwright Global Life Sciences Conference being held March 9 and 10, 2021
The Company’s presentation will be available on-demand to conference registrants.
In addition, Apexigen will be meeting with investors at the following investor conferences:
Cowen’s 41st Annual Healthcare Conference, being held March 1 to 4, 2021
Needham Virtual Healthcare Conference, being held April 12 to 15, 2021
Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents that may harness the patient’s immune system to combat and eradicate cancer. APX005M and Apexigen’s other programs were discovered using Apexigen’s proprietary APXiMAB™ discovery platform. This platform has enabled Apexigen and its various licensees to discover and develop high-quality therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies. Seven product or product candidates discovered using APXiMAB™ are currently commercially available or in clinical development, either internally by Apexigen or by its licensees. For more information, please visit www.apexigen.com.
Sr. Vice President, Business Development